Belal Hijji | Pharmacology | Best Researcher Award

Belal Hijji | Pharmacology | Best Researcher Award

Assist. Prof. Dr. Belal Hijji, Prince Sattam Bin Abdulaziz University, Saudi Arabia

Assistant Professor Dr. Belal Hijji is a distinguished nursing academic with a Ph.D. in Adult Health Nursing from the University of Ulster, UK. He has served in academic and clinical roles across Jordan, Saudi Arabia, Libya, and the UAE. With a strong focus on blood transfusion safety, he has authored books and peer-reviewed articles, including in Journal of Clinical Nursing and Nursing Reports. Dr. Hijji is passionate about nursing education, patient safety, and ethical research, and is fluent in both Arabic and English. He currently teaches at Prince Sattam bin Abdulaziz University, KSA.

Publication Profile

Google Scholar

Education

Assist. Prof. Dr. Belal Hijji is a distinguished academic with a robust background in nursing education and research. He earned his Bachelor of Nursing from Yarmouk University, Jordan (1983–1987), followed by an MSc in Nursing Studies from the University of Manchester, UK (1999–2001), where he conducted a thesis on students’ perceptions of nursing as a career. He later achieved a Ph.D. in Adult Health Nursing from the University of Ulster, UK (2003–2007), focusing on blood transfusion practices among nurses in Abu Dhabi. 🧠 In 2017, he also earned certification in human research participant protection from the NIH.

Awards

Assist. Prof. Dr. Belal Hijji has enriched his professional journey through a variety of specialized training courses. His early learning included managing hypertension and heart failure (1987) and infection control in London (1996). 🏥 He attended the 2nd GCC Seminar on Gerontology in Abu Dhabi (1997) and gained critical appraisal skills in Oxford (2000). He also participated in conferences on healthcare ethics (2002), medical statistics (2004), and qualitative research at the University of Ulster. 📊 His continuous learning extended through webinars on learning psychology (2022) and contributing to the UN Sustainable Development Goals (2022). 🌍 Lifelong learning remains his driving force.

Experience

Assist. Prof. Dr. Belal Hijji has held numerous academic and clinical roles across the Arab world. Since September 2019, he has served as Assistant Professor of Nursing at Prince Sattam bin Abdulaziz University, KSA. 🇸🇦 Previously, he taught at Al Ghad International Colleges (2015–2019), Benghazi University, Libya (2012–2015), and the University of Ha’il (2011–2012). 🏫 Earlier roles include Assistant Professor at Philadelphia University, Jordan (2008–2010). From 1987 to 2005, he worked in diverse clinical and administrative positions within regional ministries of health. 🏥 His leadership also included overseeing scientific affairs and curriculum development. 📘 His dedication to nursing education spans decades.

Research Focus

Assistant Professor Dr. Belal Hijji’s research primarily centers on blood transfusion knowledge and safety among nurses, with a strong emphasis on nursing education, clinical practice, and assessment tools. His studies span diverse healthcare settings in Jordan and the UAE, investigating nurses’ competencies, transfusion practices, and educational gaps. Additionally, he explores the effectiveness of assessment tools like multiple-choice questions and mathematical skills in dosage calculation, highlighting critical aspects of nursing proficiency. Through observational studies and survey research, Dr. Hijji contributes valuable insights into improving patient safety and enhancing nursing curricula.

Publication Top Notes

Knowledge of blood transfusion among nurses

Measuring knowledge of blood transfusion: A survey of Jordanian nurses

Nurses’ practice of blood transfusion in the United Arab Emirates: an observational study

Flaws of multiple choice questions in teacher-constructed nursing examinations: A pilot descriptive study

Trained nurses’ knowledge and practice of oral care on three wards in acute care hospital in Abu Dhabi, UAE

Item Analysis of the Modified Version of the Routine Blood Transfusion Knowledge Questionnaire

Knowledge and practice of blood transfusion: A survey of nurses in Abu Dhabi, United Arab Emirates

An Indispensable Requirement for Medical Dosage Calculation: Basic Mathematical Skills of Baccalaureate Nursing Students

The Science of Multiple-Choice Questions (MCQs)

Yu Liu | Drug Discovery and Development | Best Researcher Award

Yu Liu | Drug Discovery and Development | Best Researcher Award

Mr. Yu Liu, China Institute of Pharmaceutical Industry Co., Ltd, China

Dr. Liu Yu (b. January 11, 1981, Hengyang, Hunan) is a distinguished researcher and doctoral supervisor specializing in medicinal chemistry. He earned his Ph.D. from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (2011). Currently, he serves as Deputy Director at the China National Institute for the Control of Pharmaceutical and Biological Products and the Shanghai Drug Synthesis Process Engineering Technology Research Center. He is also a standing committee member of the Health Economics Theory and Policy Committee. Dr. Liu plays a pivotal role in pharmaceutical research and technology transfer in China.

Publication Profile

Scopus

Education

Mr. Yu Liu pursued his education in Medicinal Chemistry 🧪 at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences 🎓. He was enrolled as a full-time student from September 2008 to July 2011 📅. During this period, he dedicated himself to advanced research in the field, ultimately earning a Doctorate degree 🎖️. His studies focused on the development of medicinal compounds and pharmaceutical innovations, contributing to the field of drug discovery and development 💊. With a strong academic foundation, Mr. Liu gained expertise in chemical synthesis and pharmacology, preparing him for a successful career in medicinal sciences 🔬.

Professional Leadership

Mr. Yu Liu serves as the Deputy Director 🏛️ at both the Technology Transfer Center, China National Institute for the Control of Pharmaceutical and Biological Products and the Shanghai Drug Synthesis Process Engineering Technology Research Center 🔬. In these roles, he plays a pivotal part in advancing pharmaceutical and biotechnology research 💊. His leadership drives innovation in drug development and synthesis, ensuring progress in the field of medicinal chemistry 🧪. With his extensive expertise, Mr. Liu significantly contributes to technology transfer, regulatory advancements, and pharmaceutical innovation, reinforcing his influence in the global healthcare industry 🌍.

Experience

Mr. Yu Liu is an esteemed member of high-level academic committees 🏛️, including the Standing Committee of the Health Economics Theory and Policy Professional Committee under the Chinese Association of Health Economics 📊. His active participation in these organizations reflects his dedication to bridging scientific innovation and economic policy in healthcare 💡💰. By contributing to policy development and strategic decision-making, he plays a crucial role in shaping the future of health economics and pharmaceutical advancements 💊. His interdisciplinary expertise ensures a significant impact on both scientific research and economic frameworks, fostering innovation in healthcare systems 🌍.

Research Focus

Yu Liu’s research focuses on analytical chemistry, particularly in pharmaceutical analysis. His expertise lies in the development and validation of advanced chromatographic techniques, such as GC (Gas Chromatography) and HPLC-RID (High-Performance Liquid Chromatography with Refractive Index Detection). His work involves identifying and quantifying related substances in pharmaceutical compounds, including novel impurities in tetrabenazine. His contributions ensure drug purity, safety, and efficacy, making a significant impact on quality control and regulatory compliance in the pharmaceutical industry. His research bridges analytical chemistry and pharmaceutical sciences, advancing drug formulation and safety.

Publication Top Notes

GC and HPLC-RID method development and validation for the determination of twelve related substances, including several novel compounds in tetrabenazine

Prof. Fatma YURT|pharmaceuticals | Best Researcher Award

Prof. Fatma YURT |pharmaceuticals|Best Researcher Award|

Prof. Fatma YURT atEge University,Turkey

PROFILE  

scopus

Orcid

Early Academic Pursuits 🎓

Prof. Dr. Fatma Yurt’s journey into the scientific world began at Ege University, one of Turkey’s leading institutions. She completed her undergraduate studies at the Faculty of Science in the Department of Chemistry between 1982 and 1987. Her passion for science and dedication to learning set the stage for her illustrious career in nuclear sciences. Following her bachelor’s degree, she pursued a doctorate at Ege University in the Institute of Nuclear Sciences, specializing in Nuclear Sciences. From 1991 to 1998, she immersed herself in the study of nuclear applications, gaining a deep understanding of the field’s complexities and potential. This period of intense academic focus and research laid a solid foundation for her future contributions to nuclear medicine, radiopharmacy, and related fields.

Professional Endeavors 💼

Prof. Dr. Fatma Yurt’s professional career is marked by her steady rise through the academic ranks at Ege University. She began her career as a Research Assistant in the Nuclear Applications Department of the Institute of Nuclear Sciences, where she served from 1994 to 1997. This role allowed her to engage in cutting-edge research and contribute to the development of nuclear sciences in Turkey.

In 1999, she was promoted to Assistant Professor, and later in the same year, she achieved the rank of Associate Professor. Her commitment to education and research was evident as she continued to mentor students and lead research projects in nuclear applications. By 2007, she had earned the title of Professor, solidifying her position as a leading expert in her field.

Prof. Dr. Yurt’s expertise is not limited to academia; she has also held significant administrative roles. Since 2016, she has served as the Director of the Institute of Nuclear Sciences at Ege University. In this capacity, she has been instrumental in shaping the direction of nuclear research and education in Turkey, overseeing various projects and initiatives that have expanded the institute’s influence both nationally and internationally.

Contributions and Research Focus 🔬

Prof. Dr. Fatma Yurt’s research spans several critical areas within nuclear sciences, with a particular emphasis on nuclear medicine, radiopharmacy, and pharmacology. Her work in these fields has been pivotal in advancing the understanding and application of nuclear techniques in medicine, particularly in diagnosing and treating various diseases.

Her research contributions include the development of novel radiopharmaceuticals, which are essential for diagnosing and treating conditions such as cancer. Prof. Dr. Yurt’s expertise in nuclear chemistry and physical chemistry has enabled her to explore the intricate processes involved in the synthesis and application of these compounds. She has also contributed significantly to the field of health sciences, particularly in the areas of internal medicine and pharmaceutical technology.

With a Scopus publication count of 123 and a Unisis publication count of 296, Prof. Dr. Yurt’s research output is impressive. Her work has been cited over 1,447 times on Scopus, reflecting the impact and relevance of her research. Her H-Index, a measure of both the productivity and citation impact of her publications, stands at 21 on Scopus, further underscoring her influence in the field.

Accolades and Recognition 🏆

Throughout her career, Prof. Dr. Fatma Yurt has received numerous accolades and recognition for her contributions to nuclear sciences and medicine. Her research has been widely acknowledged by her peers, and she has been invited to present her findings at various national and international conferences. Her role as the Director of the Institute of Nuclear Sciences is a testament to her leadership abilities and her dedication to advancing the field of nuclear applications.

Prof. Dr. Yurt’s work has not only advanced scientific understanding but has also had a tangible impact on healthcare. Her contributions to radiopharmacy have been particularly significant, with her research playing a crucial role in the development of new diagnostic and therapeutic methods. Her dedication to her field is further demonstrated by her ongoing involvement in academic mentorship, helping to train the next generation of scientists in nuclear sciences.

Impact and Influence 🌍

Prof. Dr. Yurt’s influence extends beyond her research and academic roles. As a leader in nuclear sciences, she has been instrumental in promoting the importance of nuclear applications in medicine and other fields. Her work has helped to bridge the gap between basic research and practical applications, ensuring that the benefits of nuclear science are realized in clinical settings.

Her leadership at the Institute of Nuclear Sciences has also been pivotal in shaping the research agenda in Turkey, encouraging interdisciplinary collaboration and fostering a culture of innovation. Under her guidance, the institute has strengthened its position as a center of excellence in nuclear research, attracting students and researchers from around the world.

Legacy and Future Contributions 🌟

Prof. Dr. Fatma Yurt’s legacy is one of dedication, innovation, and leadership. Her contributions to nuclear medicine, radiopharmacy, and related fields have had a lasting impact on both the scientific community and the broader healthcare sector. As she continues her work, her influence will undoubtedly grow, inspiring new research and leading to further advancements in nuclear applications.

🎓Publication 

An in vitro evaluation of Hypericum perforatum loaded-chitosan nanoparticle/agarose film as a Wound dressing

Unveiling combat strategies against Candida spp. biofilm structures: Demonstration of photodynamic inactivation with innovative phthalocyanine derivatives

Platinum (II) Schiff Base Complexes and their Effects on the Inhibition of Amyloid β1–42 Aggregation

In Vitro Assessment of 177Lu-Labeled Trastuzumab-Targeted Mesoporous Carbon@Silica Nanostructure for the Treatment of HER2-Positive Breast Cancer

  • Authors   :Tunçel, A., Maschauer, S., Prante, O., Yurt, F.
  • Journal    :Pharmaceuticals
  • Year         :2024